EFFECTS OF AVEMAR® IN CANCERS OF THE ORAL CAVITY
 An open, comparative study

 

Back to Clinical pages Print this page


Center: Clinic of Oral and Maxillofacial Surgery, Semmelweis University, Budapest
Principal investigator: Prof. Dr. György Szabó MD, PhD, DSc, Director of Clinic
Duration of study: 1999-2001
Number of patients: Avemar Group: 22 pts; Control Group : 23 pts
Mean duration of Avemar treatment: 12 months
Staging of patients at baseline:
 

UICC staging  Control   Avemar
 
Number of pts %  Number of pts %
II 11 47.8  11 50
III 12 52.2 11 50
  
Results
 
Occurrence of progression-related events (end-point analysis).
 

 

Avemar (n = 22)

control (n = 23)

 

#

%

#

%

patients with new recurrent disease1

1

4.3

12

54.5

patients with new metastatic lesions2

1

4.3

4

18.2

deaths3

0

0

1

4.5

overall progression events4

2

8.7

17

77.3

 

 
 
 
 
 
 
1p < 0.001. 2N.S. 3N.S. 4p < 0.001
 
Conclusions: According to the risk-reduction analysis, Avemar treatment resulted in 85.3 % reduction of the risk of progression. Furthermore, the so called Number-Needed-to-Treat is 2, which means that 1-year treatment of 2 patients with Avemar is needed to completely avoid the progression in 1 patient.
 

 

Back to Clinical pages Print this page

 

 

.       Powered by webEFEKTs.